Bainbridge-Ropers syndrome is a neurodevelopmental genetic disorder associated with mutations in the additional sex combs–like ASXL3 gene on chromosome 18q12.1. This study describes the comorbid psychiatric aspects of this disorder.
Dr Post discusses the epigenetic marks left by environmental stressors and deprivation and their consequences for the physical and mental health of blacks in the US.
Psychiatric symptoms in empty sella are uncommon, but empty sella syndrome has been reported to be present along with psychosis. This report presents a case of Wilson’s disease with psychotic presentation and empty sella syndrome in an adolescent.
Although the tetralogy of Fallot (TOF) may be associated with psychiatric disorders, the risk of this association has not been well documented. This nationwide cohort study investigated the long-term risk of psychiatric disorders in TOF patients.
Should recurrence of toxicity after reintroduction of a serotoninergic drug prompt the investigation of a genetic polymorphism for hepatic metabolism? Read this case report to find out more.
Do you know what to say if a patient asks about genetic testing for a particular condition? This review from the International Society of Psychiatric Genetics discusses challenges and presents recommendations about the need for informed genetic counseling in psychiatry. Read the article and delve into this increasingly important topic.
Turner syndrome is a genetic disorder in females characterized by partial or complete X chromosome monosomy. These individuals are at increased risk for autism spectrum disorders, ADHD, intellectual disability, and schizophrenia. Read this case of a woman with Turner syndrome who experienced psychotic symptoms. Could she have schizophrenia?
Early-onset bipolar disorder may represent a distinct phenotype with greater severity, but the genetics of it are still poorly understood. This study used candidate genetic risk score analysis to identify polymorphisms associated with early-onset bipolar disorder.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT